Atopic Dermatitis and Mental Comorbidities
Authors:
M. Anders 1; S. Gkalpakiotis 2; F. Rob 3; M. Salavec 4; A. Machovcová 5; M. Selerová 6; H. Obluková 7; E. Kitzlerová 1
Authors place of work:
Psychiatrická klinika 1. LF UK a VFN v Praze, přednosta doc. MUDr. Martin Anders, Ph. D.
1; Dermatovenerologická klinika 3. LF UK a FNKV, Praha, přednosta prof. MUDr. Petr Arenberger, DrSc., MBA, FCMA
2; Dermatovenerologická klinika 2. LF UK a FNB, Praha, přednosta doc. MUDr. Filip Rob, Ph. D.
3; Klinika nemocí kožních a pohlavních LF UK v Hradci Králové a FN Hradec Králové, přednosta doc. MUDr. Miloslav Salavec, CSc.
4; Dermatovenerologické oddělení FNM, Praha, primářka MUDr. Alena Machovcová, Ph. D., MBA
5; Dermatovenerologické oddělení Nemocnice Agel Nový Jičín, primářka MUDr. Jana Chlebková
6; Dětské kožní oddělení Pediatrické kliniky FN Brno, primářka MUDr. Blanka Pinková, Ph. D.
7
Published in the journal:
Čes-slov Derm, 97, 2022, No. 5, p. 196-208
Category:
Pharmacologyand Therapy, Clinical Trials
Summary
Atopic dermatitis is an inflammatory skin disease associated with an increased risk of a number of comorbidities, including mental disorders, which can worsen the course of the skin disease. The most common mental comorbidities include depressive disorder, anxiety disorder, attention deficit, hyperactivity disorder, autism and increased suicidal activity (suicidal thoughts or self-harm in suicidal ideation). Pathophysiology is multifactorial, currently there is increasing evidence of the involvement of multiple immune mechanisms, stress, sleep deprivation and other socioeconomic and behavioral factors play an important role. Concerning the course and prognosis of atopic dermatitis, mental comorbidities must be recognized in time. Simple instruments in the form of selfevaluation scales can be used for detection. Treatment should take place in collaboration with psychiatrists and psychologists using targeted psychotropic drugs or psychotherapy. Hope in the treatment of atopic dermatitis are monoclonal antibodies directed against pro-inflammatory cytokines, which could bring relief to patients also in the area of mental health.
Keywords:
etiopathogenesis – atopic dermatitis – treatment – psychological comorbidities
Zdroje
1. ABUABARA, K., YU, A. M., OKHOVAT, J. P. et al. The prevalence of atopic dermatitis beyond childhood: A systematic review and meta-analysis of longitudinal studies. Allergy, 2018, 73, p. 696–704.
2. ALEXANDER, F. Psychosomatic medicine. New York: Norton; 1950.
3. ANDERS, M. Psychofarmaka ve vnitřním lékařství. In Marek, J., Vráblík, M.: Markova farmakoterapie vnitřních nemocí; 5. zcela přepracované a doplněné vydání. Praha, 2019, s. 689–715.
4. ARROLL, B., KHIN, N., KERSE, N. Screening for depression in primary care with two verbally asked questions: cross sectional study. BMJ, 2003, 15, 327(7424), p. 1144–1146.
5. BATESON, A. N. The benzodiazepine site of the GABAA receptor: an old target with new potential? Sleep Med., 2004, 5(suppl1), p. S9–S15.
6. BECK, A. T., STEER, R. A., BALL, R. et al. Comparison of Beck Depression Inventories – IA and -II in psychiatric outpatients. J Pers Assess, 1996, 67, p. 588–597.
7. BENCA, R., PETERSON, M. Insomnia and depression. Sleep Medicine, 2008, 9 (Suppl. 1), p. S3–S9.
8. CIPRIANI, A., FURUKAWA, T. A., SALANTI, G. et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet, 2018, 391(10128), p. 1357–1366. doi: 10.1016/S0140- 6736(17)32802-7.
9. COE, C. L., LUBACH, G. R. Mother-infant interactions and the development of immunity from conception through weaning. In: Ader, R. editor. Psychoneuroimmunology. Amsterdam: Academic Press, 2007, p. 455–474.
10. DABADE, T. S., DAVISDM, WETTERDA, et al. Wet dressing therapy in conjunction with topical corticosteroids is effective for rapid control of severe pediatric atopic dermatitis: experience with 218 patients over 30 years at Mayo Clinic. J Am Acad Dermatol., 2012, 67(1), p. 100–106.23.
11. DECKERT, S., KOPKOW, C., SCHMITT, J. Nonallergic comorbidities of atopic eczema: an overview of systematic reviews. Allergy, 2014, 69, p. 37–45.
12. DRAKE, L. A., MILLIKAN, L. E. Doxepin Study Group: The antipruritic effect of 5% doxepin cream in patients with eczematous dermatitis. Arch Dermatol, 131(12), p. 1403– 1408, 1995 7492129.
13. EBATA, T., IZUMI, H., AIZAWA, H. et al. Effects of nitrazepam on nocturnal scratching in adults with atopic dermatitis: a double-blind placebo-controlled crossover study. Br J Dermatol, 138(4), p. 631– 634, 1998 9640368.
14. GARG, N., SILVERBERG, J. I. Association between childhood allergic disease, psychological comorbidity, and injury requiring medical attention. Ann Allergy Asthma Immunol, 2014, 112, p. 525–532.
15. GONZÁLEZ, E., SANGUINO, R. M., FRANCO, M. A. Bupropion in atopic dermatitis. Pharmacopsychiatry, 2006, 39(6), 229, 17124645.
16. GUPTA, M. A., GUPTA, A. K. Sleep-wake disorders and dermatology. Clin Dermatol, 2013, 31(1), p. 118– 126.
17. HALVORSEN, J. A., DALGARD, F., THORESEN, M. et al. Itch and pain in adolescents are associated with suicidal ideation: a population-based cross-sectional study. Acta Derm Venereol., 2012, 92(5), p. 543–546. doi:10.2340/00015555-1251.
18. HUNDLEY, J. L., YOSIPOVITCH, G. Mirtazapine for reducing nocturnal itch in patients with chronic pruritus: a pilot study. J Am Acad Dermatol, 2004, 50(6), p. 889–891, 15153889.
19. CHANG, Y. S., CHOU, Y. T., LEE, J. H. et al. Atopic dermatitis, melatonin, and sleep disturbance. Pediatrics, 2014, 134(2), p. e397–e405.
0. CHANG, Y. S., LIN, M. H., LEE, J. H. et al. Melatonin supplementation for children with atopic dermatitis and sleep disturbance: a randomized clinical trial. JAMA Pediatr, 2016, 170(1), p. 35–42.
21. CHELLAPPA, S. L., STEINER, R., OELHAFEN, P. et al. Acute exposure to evening blueenriched light impacts on human sleep. J Sleep Res, 2013, 22(5), p. 573–580.
22. CHIDA, Y., SUDO, N., SONODA, J. et al. Early-life psychological stress exacerbates adult mouse asthma via the hypothalamus-pituitary-adrenal axis. Am J Respir Crit Care Med., 2007, 175(4), p. 316–322. doi: 10.1164/rccm.200607-898OC. Epub 2006 Nov 16. PMID: 17110645.
23. CHIESA FUXENCH, Z. C., BLOCK, J., BOGUNIEWICZ, M. et al. Atopic Dermatitis in America Study: a crosssectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population. J Invest Dermatol, 2019, 139, p. 583–590.
24. KAMARÁDOVÁ, D., PRAŠKO, J., LÁTALOVÁ, K. et al. Validizace české verze Beckova inventáře úzkosti. Čes a slov Psychiat, 2016, 112(4), p. 153–158.
25. KAYE, A. D., KAYE, A. J., SWINFORD, J. et al. The effect of deep-tissuemassage therapy on blood pressure and heart rate. J Altern Complement Med, 2008, 14(2), p. 125–128.
26. KELSAY, K. Management of sleep disturbance associated with atopic dermatitis. J Allergy Clin Immunol, 2006, 118(1), p. 198–201.
27. KIM, Y., BLOMBERG, M., RIFAS-SHIPMAN, S. L. et al. Racial/ethnic differences in incidence and persistence of childhood atopic dermatitis. J Invest Dermatol, 2019, 139, p. 827–834.
28. KLEIN, P. A., CLARK, R. A. An evidence-based review of the efficacy of antihistamines in relieving pruritus in atopic dermatitis. Arch Dermatol, 1999, 135(12), p. 1522–1525.
29. KONG, T. S., HAN, T. Y., LEE, J. H. et al. Correlation between severity of atopic dermatitis and sleep quality in children and adults. Ann Dermatol., 2016, 28(3), p. 321–326. doi:10.5021/ad.2016.28.3.321.
30. KOO, J., MARANGELL, L. B., NAKAMURAM et al. Depression and suicidality in psoriasis: review of the literature including the cytokine theory of depression. J Eur Acad Dermatol Venereol., 2017, 31(12), p. 1999–2009. doi:10.1111/jdv.14460.
31. KROENKE, K., SPITZER, R. L., WILLIAMS, J. B. et al. Physical symptoms in primary care. Predictors of psychiatric disorders and functional impairment. Arch Fam Med., 1994, 3 (9), p. 774–779.
32. KUPFER, D. J., REYNOLDS, C. F. Management of insomnia. N Engl J Med., 1997, 336, p. 341.
33. LANGAN, S. M., IRVINE, A. D., WEIDINGER, S. Atopic dermatitis. Lancet, 2020, 396(10247), p. 345–360. doi: 10.1016/S0140-6736(20)31286-1. Erratum in: Lancet, 2020, 396(10253), p. 758. PMID: 32738956.
34. LEE, S., SHIN, A. Association of atopic dermatitis with depressive symptoms and suicidal behaviors among adolescents in Korea: the 2013 Korean Youth Risk Behavior Survey. BMC Psychiatry, 2017, 17, p. 3.
35. LEVENSON, J. Psychiatric issues in dermatology, part 1: atopic dermatitis and psoriasis. Prim psychiatry, 2008, 15, p. 31–34.
36. LIAO, T. C., LIEN, Y. T., WANG, S. et al. Comorbidity of atopic disorders with autism spectrum disorder and attention deficit/hyperactivity disorder. J Pediatr., 2016, 171, p. 24–55.
37. LIM, V. Z., HO, R. C., TEE, S. I. et al. Anxiety and depression in patients with atopic dermatitis in a Southeast Asian tertiary dermatological centre. Ann Acad Med Singapore, 2016, 45(10), p. 451–455.
38. LINDQVIST, D., JANELIDZE, S., HAGELL, P. et al. Interleukin- 6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity. Biol Psychiatry, 2009, 66(3), p. 287–292. doi: 10.1016/j.biopsych.2009.01.030. Epub 2009 Mar 6. PMID: 19268915.
39. MAHTANI, R., PAREKH, N., MANGAT, I. et al. Alleviating the itch-scratch cycle in atopic dermatitis. Psychosomatics, 2005, 46(4), p. 373–374, 16000683.
40. MARSHALL, G. D., ROY, S. R. Stress and allergic diseases. In: Ader R, editor. Psychoneuroimmunology. Amsterdam: Academic Press; 2007, p. 799–824.
41. MASON, R. Fabrics for atopic dermatitis: Dr Rupert Mason discusses the pros and cons of different fabrics for use in atopic dermatitis. J Fam Health Care, 2008, 18(2), p. 63–66.
42. MCDOUGLE, C. J. Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders. Accessed December 3, 2018. Available at: https:// ClinicalTrials.gov/show/ NCT01302964.
43. MCEWEN, B. S. Protective and damaging effects of stress mediators. N Engl J Med., 1998, 338, p. 171– 179.
44. MODELL, J. G., BOYCE, S., TAYLOR, E. et al. Treatment of atopic dermatitis and psoriasis vulgaris with bupropion-SR: a pilot study. Psychosom Med, 2002, 64(5), p. 835–840, 12271115.
45. National Institute for Health and Care Excellence. NICE clinical guideline 90 Depression: The treatment and management of depression in adults. 2009.
46. NEUBAUER, D. N. Chronic insomnia: current issues. Clin Cornerstone, 2004, 6(suppl1C), p. S17–S22.
47. NICHOLSON, A. The use of short-and long-acting hypnotics in clinical medicine. Br J Clin Pharmacol, 1981, 11(S1), p. 61S–69S.
48. NOH, H. M., CHO, J. J., PARK, Y. S. et al. The relationship between suicidal behaviors and atopic dermatitis in Korean adolescents. J Health Psychol., 2016, 21(10), p. 2183–2194. doi:10.1177 /1359105315572453.
49. NORRESLET, L. B., EBBEHOJ, N. E., ELLEKILDE, BONDE, J. P. et al. The impact of atopic dermatitis on work life: a systematic review. J Eur Acad Dermatol Venereol., 2018, 32(1), p. 23–38. doi:10 .1111/ jdv.14523.
50. OLIVEIRA, C., TORRES, T. More than skin deep: the systemic nature of atopic dermatitis. Eur J Dermatol., 2019, 29(3), p. 250–258.
51. OWENS, J. A., MINDELL, J. A. Pediatric insomnia. Pediatr Clin North Am, 2011, 58 (3), p. 555–569.
52. PALLER, A., JAWORSKI, J. C., SIMPSON, E. L. Major Comorbidities of Atopic Dermatitis: Beyond Allergic Disorders. American Journal of Clinical Dermatology. Dostupné na www: https://doi.org/10.1007/ s40257-018-0383-4.
53. REID, P., LEWIS-JONES, M. Sleep difficulties and their management in preschoolers with atopic eczema. Clin Exp Dermatol., 1995, 20(1), p. 38–41.
54. RIIS, J. L., VESTERGAARD, C., DELEURAN, M. S. et al. Childhood atopic dermatitis and risk of attention deficit/hyperactivity disorder: a cohort study. J Allergy Clin Immunol, 2016, 138, p. 608–610.
55. SANDHU, J., KEVIN, K. W. U., THAN-LAN BUI, M. A. et al. Association between Atopic Detrmatitis and Suicidality. A systemativ review and Meta-analysis. JAMA Dermatology, 2018, doi:10.1001/jamadermatol. 2018.4566.
56. SANGER, D. J. The pharmacology and mechanisms of action of new generation, non-benzodiazepine hypnotic agents. CNS Drugs, 2004, 18(suppl1), p. 9–15.
57. SAVIN, J. A., PATERSON, W. D., ADAM, K. et al. Effects of trimeprazine and trimipramine on nocturnal scratching in patients with atopic eczema. Arch Dermatol, 115(3), p. 313– 315, 1979 373632.
58. SHANI-ADIR, A., ROZENMAN, D., KESSEL, A. et al. The relationship between sensory hypersensitivity and sleep quality of children with atopic dermatitis. Pediatr Dermatol., 2009, 26(2), p. 143–149.
59. SHIN, J., CHOI, Y., PARK, E.-C. et al. Psychiatry outpatient visits by atopic dermatitis patients varying in the complexity of their prescriptions. Medicine (Baltimore), 2016, 95, p. e5411.
60. SCHACHNER, L., FIELD, T., HERNANDEZ-REIF, M. et al. Atopic dermatitis symptoms decreased in children following massage therapy. Pediatr Dermatol, 1998, 15(5), p. 390–395.
61. SCHMITT, J., CHEN, C. M., APFELBACHER, C. et al. Infant eczema, infant sleeping problems, and mental health at 10 years of age: the prospective birth cohort study LISAplus. Allergy, 2011, 66, p. 404–411.
62. SCHONMANN, Y., MANSFIELD, K. E., HAYES, J. F. Atopic eczema in adulthood and risk of depression and anxiety: a population-based cohort study. J Allergy Clin Immunol Pract, 2020, 8, p. 248–257.
63. SIDBURY, R., DAVIS, D. M., COHEN, D. E. et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol, 2014, 71(2), p. 327–349.
64. SILVERBERG, J. I., GARG, N. K., PALLER, A. S. et al. Sleep disturbances in adults with eczema are associated with impaired overal health: a US population- based study. J Invest Dermatol, 2015, 135, p. 56–66.
65. SILVERBERG, J. I., HANIFIN, J. M. Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population- based study. J Allergy Clin Immunol., 2013, 132, p. 1132–1138.
66. SILVERBERG, J. I., SIMPSON, E. L. Association between severe eczema in children and multiple comorbid conditions and increased healthcare utilization. Pediatr Allergy Immunol., 2013, 24, p. 476– 486.
67. SILVERBERG, J. I., SIMPSON, E. L. Associations of childhood eczema severity: a US population-based study. Dermatitis, 2014, 25(3), p. 107–114. doi:10.1097 /DER.0000000000000034.
68. SILVERBERG, J. I. Public health burden and epidemiology of atopic dermatitis. Dermatol Clin., 2017, 35(3), p. 283–289. doi:10.1016/j.det.2017.02.002.
69. SIMPSON, E. L., AKINLADE, B., ARDELEANU, M. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med., 2017, 376(11), p. 1090–1091.
70. SIMPSON, E. L., GUTTMAN-YASSKY, E., MARGOLIS, D. J. et al. Association of inadequately controlled disease and disease severity with patient-reported disease burden in adults with atopic dermatitis. JAMA Dermatol., 2018, 154(8), p. 903– 912. doi:10.1001 /jamadermatol.2018.1572.
71. SPITZER, R. L., KROENKE, K., WILLIAMS, J. B. et al. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med., 2006, 166(10), p. 1092–1097.
72. TUREK, F. W., GILLETTE, M. U. Melatonin, sleep, and circadian rhythms: rationale for development of specific melatonin agonists. Sleep Med., 2004, 5(6), p. 523–532.
73. WEIDINGER, S., NOVAK, N. Atopic dermatitis. Lancet, 2016, 387, p: 1109–1122.
74. WILSON, S., ARGYROPOULOS, S. Antidepressants and sleep. Drugs, 2005, 65(7), p. 927–947.
75. WRIGHT, R. J., COHEN, R. T., COHEN, S. The impact of stress on the development and expression of atopy. Curr Opin Allergy Clin Immunol., 2005, 5, p. 23–29.
76. WRIGHT, R. J. Stress and atopic disorders. J Allergy Clin Immunol., 2005, 116, p. 1301–1306.
77. YAGHMAIE, P., KOUDELKA, C. W., SIMPSON, E. L. Mental health comorbidity in patients with atopic dermatitis. J Allergy Clin Immunol., 2013, 131, p. 428– 433.
Štítky
Dermatology & STDs Paediatric dermatology & STDsČlánok vyšiel v časopise
Czech-Slovak Dermatology
2022 Číslo 5
Najčítanejšie v tomto čísle
- Atopic Dermatitis and Mental Comorbidities
- Verukózní útvar na plosce
- Dermoscopy – Physics in the Hands of a Dermatologist
- Kalendář odborných akcí